LJgnocaine was administered to patients undergoing cardiopulmonary bypass at 28-29°C in bolus doses of 1.5, 2.5 and 3.5mgkg~'. Plasma concentrations greater than 1.5ngml~' were found briefly and inconsistently in patients receiving the usually recommended dose (l.Smgkg" 1 ), but reliably for 14min in those receiving 2.5mgkg~1. The S.Smgkg" 1 dose produced statistically and clinically significant decreases in mean arterial pressure. Examination of calculated kinetic parameters showed a two-fold decrease in Tj", two-fold increases in Tj' and V and unaltered C/p and Vp when compared with those of unanaesthetized, normothermic patients. The alteration in pharmacokinetics may be attributed largely to decreased binding to albumin following haemodilution.
With the use of present methods of myocardial preservation during cardiopulmonary bypass (CPB), ventricular arrhythmias at the end of the procedure pose less of a problem than previously. Antiarrhythmic agents are seldom indicated, but on those occasions when they are required, lignocaine is selected most frequently. In normal subjects the effective plasma concentration of the drug against ventricular arrhythmias is greater than l.Sngml" 1 (Grossman, Cooper and Frieden, 1969) . This study was undertaken to determine the dose required to achieve this concentration during CPB.
PATIENTS AND METHODS
Twenty-four patients undergoing surgery for valve replacement or coronary artery bypass grafts were studied.
Anaesthesia included the use of morphine, halothane and nitrous oxide in oxygen, following the induction of anaesthesia with sufficient thiopentone to abolish the eyelash reflex. Neuromuscular blockade was produced (pancuronium) and ventilation controlled mechanically. The extracorporeal circulation was powered by Saras Moduler roller pumps and used bubble oxygenators (Polystan Venothenn VT 5000). The bypass technique included haemodilution and cardioplegia with moderate hypothermia (28-29°C). The pump priming volume was 3 litre of balanced salt solution (Plasmalyte B), and pump flow was calculated on the basis of 2.4 litre/m 2 body surface area. Blood-gas tensions, pH and plasma potassium concentration were kept constant throughout CPB.
Once cardiovascular conditions had stabilized on CPB at 28-29°C, Lignocaine was injected over 30 s to a port immediately below the bubble oxygenator. The bolus doses of lignocaine administered were (1) l.Smgkg" 1 in 10 patients, (2) 2.5mgkg~1 in nine patients, and (3) 3.5mgkg~' in five patients. The mean (± SD) doses for the three groups were 105.5 (± 28.9), 163 (± 40.6), and 218.5 (± 50) mg, respectively. The largest dose was abandoned after use in five patients because of unacceptable decreases in mean arterial pressure (MAP).
Blood samples were aspirated from the oxygenator debubbler at 2, 4, 6, 8, 10, 15, 20 and 30min after injection. Although we recognize the sampling period to be shorter than ideal for a pharmacokinetic study, this limitation was required because of the duration of CPB. Plasma concentrations of lignocaine were assayed by gas-liquid chromatography (Morrell, Chappell and White, 1982) . Other biochemical measurements included total protein and albumin concentrations.
From the plasma lignocaine assay data, coefficients and exponents for the concentration curve for each patient were calculated using the Fortran IV program CSTRIP (Sedman and Wagner, 1976) , and pharmacokinetic parameters (table I) were calculated using formulae described by Wagner (1976) . The R 2 value obtained from CSTRIP was always better than 0.98. 
RESULTS
The mean plasma lignocaine decay curves following the three different doses are shown in figure 1 . A decrease to l.S^gml" 1 occurred within 3, 14 and more than 30 min following bolus injections of 1.5, 2.5 and S.Smgkg" 1 , respectively. Only 60% of patients receiving the usually recommended dose of l.Smgkg" 1 were found to have plasma concentrations above 1.5 \i% ml" 1 at 2 min, declining to 10% at 4min. While the concentration of 1.5/igml" 1 was achieved for 4 min in all patients receiving the intermediate-sized dose of 2.5 mg kg"', it was maintained at 30 min in 10% of this group. Following the 3.5-mg kg" 1 bolus, lignocaine concentrations were greater than 1.5 ng ml" 1 in all patients for up to 20 min, and in 60% of patients remained so at 30 min.
MAP did not change significantly in those patients receiving the two smaller doses but decreased on average by 20.5% from the pre-injection pressure of 66mmHg in those receiving S.Smgkg" 1 . The maximum individual decrease was 45% of the preinjection pressure.
Haemodilution resulted in a decrease in mean serum albumin concentration to 65% of its prebypass value, which was itself at the lower limit of the normal range (table II) . Serum protein concentrations did not alter during the experimental period. Pharmacokinetic parameters are recorded in table III. These represent the means of the values as calculated for each patient. The clinically stable sampling period was limited to 30 min and, as a result, our calculated coefficients and exponents are liable to error since a limited number of data points was obtained in the metabolic phase. Therefore, for the purpose of comparison with published work, we recalculated the data of Rowland and colleagues (1971) as if their sampling was discontinued at 30 min. The method used was to calculate from their data expected plasma concentrations at our sampling times using the coefficients and exponents provided, and then to recalculate (using CSTRIP) the exponents and coefficients for the initial 30-min period. From these, pharmacokinetic parameters were derived. The original and recalculated data are provided in table HI, rows A and B. Comparison of the data from our 1.5-mg kg" 1 bolus group (mean dose = 105.5 mg) with theirs (dose = 100 mg) reveals a halving in Tf and a doubling in 7Y, V** and V in our data relative to theirs. Clp and Vp were the same.
The extent of the error induced by the shortened sampling period is evident when the original data from Rowland's work are compared with the recalculated data (table III, row A v. row B), incurring an underestimate of half-lives and volumes of distribution and overestimate of clearance.
DISCUSSION
Although the pharmacokinetic behaviour of lignocaine and its relevance to the development of effective dosage schedules have been well reviewed in patients with normal haemodynamics, heart failure and liver or renal disease (Benowitz and Meister, 1978) , we are not aware of similar studies having been undertaken during CPB. Many factors which would influence pharmacokinetics are introduced such as anaesthetic and vasoactive drugs, hypothermia, dilution of red cell and protein concentrations, non-pulsatile flow, decreased blood viscosity and exclusion of the lung as a first-pass organ. Furthermore, whereas a total drug concentration of 1.5ngml"' has been established as necessary for antiarrhythrriic activity in the unanaesthetized patient, it is not axiomatic that this concentration applies following CPB.
The main results of this study were the low initial and rapid decrease in plasma concentrations of lignocaine during CPB. This is in keeping with the finding of altered distribution kinetics which were the two-fold decrease in Tf and two-fold increase in V and V. The metabolic handling of lignocaine as reflected by Cl P is unaltered, the increased Tf caused by the increased volumes of distribution (Hull, 1981) . The addition of an dxygenator prime on a volume basis would not significantly increase volume of distribution as it would form part of V? which, for a 70-kg man receiving a 1.5-mg kg" 1 bolus, is of the order of 37.5 litre. The additional 3 litre prime volume is thus less than 10% of Vp and would require only an additional 4.5mg of lignocaine over and above the 105-mg bolus to achieve a concentration of 1.5 fig ml" l . We feel that the explanation for the altered distribution kinetics can be attributed largely to an increase in the unbound pharmacodynamic fraction of lignocaine caused by the decrease in concentration of binding sites resulting from dilution of plasma albumin. Actual measurements of this unbound fraction were not performed in our study, but estimates may be made using published information. Drug binding to macromolecules (Koch-Weser and Sellers, 1976 ) is dependent on the total drug concentration, the macromolecular concentration, the number of binding sites per macromolecule and the dissociation constant for the drug-macromolecule complex. Applying the constants derived by Tucker and co-workers (1970) for lignocaine-albumin binding, the calculated change in bound drug concentration following the injection of a 2.5-mgkg" 1 bolus of lignocaine in our patients is shown in figure  2 . This records the decay curves for total and unbound drug at albumin concentrations of 35 and 23 g litre" 1 , representing the pre-CPB and CPB concentrations in our patients. The 35% decrease in albumin concentration following haemodilution produced an almost constant 37% increase in unbound drug concentration over the whole range of total lignocaine concentrations encountered. Furthermore, an anti-arrhythmic total drug concentration of 1.5 ng ml" 1 corresponds to an unbound drug concentration of 0.45 ngml" 1 at an albumin concentration of 35 g litre" 1 . Figure 2 demonstrates also that haemodilution to the extent of decreasing albumin concentration to 23 g litre" 1 extends the time for which the unbound drug fraction is greater than 0.45 ng ml" 1 from 14to26min.
Our results indicate that, during CPB with haemodilution, the bolus loading dose of lignocaine with which to precede a continuous infusion is 2.5mgkg" 1 rather than the more usually recommended 1.5 mg kg" 1 . The larger dose produces greater and more sustained plasma concentrations without incurring clinical changes in vascular resistance and MAP. , un doble incremento del Ttf y V™, y C/p y Vj> sin alteracion alguna cuando se compararon con los de los pacientes normotermicos anestesiados. La variacion de los aspectos farmacocineticos pueden atribuine en gran medida a la disminudon de la ligazon a la albumins a raiz de la hemodiludon.
